Projects & Grants

Projects and Grants per year 2000 2000 2007 2010 2012 2014 2024

• 19 Finished

Projects and Grants per year

Search results

• Finished

  13-NHL-21-JJ:(PCI-32765FLR3001) Ibrutinib combined with either BR or R-CHOP for relapsed iNHL

  Fleischman, R. (PI)

  Janssen Research and Development LLC

  5/19/14 → 5/31/16

  Project: Research project

• 14-HEM-05-SA (TED12414) Extension study for patients benefiting from treatment on ARD12130

  Fleischman, R. (PI)

  Sanofi Aventis US Inc

  1/1/14 → 10/31/14

  Project: Research project

• 12-NHL-18-JJ (PCI-32765MCL3002) Bendamustine-Rituximab +/- Ibrutinib for newly diagnosed Mantle Cell Lymphoma (SHINE)

  Fleischman, R. (PI) & Hayslip, J. (Former PI)

  Janssen Research and Development LLC

  5/10/13 → 7/31/24

  Project: Research project

• 12NHL14JJ BTK Inhibitor+Ibrutinib in Patients with Mantle Cell Lymphoma who Progress After Bortezomib

  Fleischman, R. (PI) & Hayslip, J. (Former PI)

  Janssen Research and Development LLC

  8/1/12 → 3/30/16

  Project: Research project

• A Phase 3 Open-Label Randomized Study to Compare the Efficacy And Safety of Rituximab Plus lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy in Subjects with Previously Untreated Follicular Lymphoma

  Fleischman, R. (PI), Monohan, G. (CoI), Hayslip, J. (Former PI) & Shakil, S. (Former CoI)

  Celgene

  4/12/12 → 8/21/23

  Project: Research project

• HEM02 (ARD130) A Phase 2 Study of SAR245409

  Fleischman, R. (PI) & Hayslip, J. (Former PI)

  Sanofi Aventis US Inc

  1/18/12 → 12/31/15

  Project: Research project

• Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidationand TNFa Release

  Hayslip, J. (PI), Butterfield, D. A. (CoI), Chambers, M. (CoI), Dressler, E. (CoI), Fleischman, R. (CoI), Howard, D. (CoI), Massarweh, S. (CoI), McDonagh, K. (CoI), Monohan, G. (CoI), Romond, E. (CoI), St Clair, D. (CoI), Moscow, J. (Former PI), Lekakis, L. (Former CoI) & Shelton, B. (Former CoI)

  National Cancer Institute

  8/1/10 → 5/31/14

  Project: Research project

  • Coenzyme M 100%
  • Plasma Protein 100%
  • Doxorubicin 100%
  • Mesna 100%
  • Blood Proteins 100%

• Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidationand TNFa Release - St. Clair Scope

  St Clair, D. (PI), Butterfield, D. A. (CoI), Chambers, M. (CoI), Fleischman, R. (CoI), Hayslip, J. (CoI), Howard, D. (CoI), Lekakis, L. (CoI), Massarweh, S. (CoI), McDonagh, K. (CoI), Monohan, G. (CoI), Moscow, J. (CoI), Romond, E. (CoI) & Shelton, B. (CoI)

  National Cancer Institute

  8/1/10 → 5/31/12

  Project: Research project

  • Coenzyme M 100%
  • Doxorubicin 100%
  • Blood Proteins 100%
  • Plasma Protein 100%
  • Mesna 100%

• Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidationand TNFa Release - Butterfield Scope

  Butterfield, D. A. (PI), Chambers, M. (CoI), Fleischman, R. (CoI), Hayslip, J. (CoI), Howard, D. (CoI), Massarweh, S. (CoI), McDonagh, K. (CoI), Monohan, G. (CoI), Moscow, J. (CoI), Romond, E. (CoI), Shelton, B. (CoI), St Clair, D. (CoI) & Lekakis, L. (Former CoI)

  National Cancer Institute

  8/1/10 → 5/31/14

  Project: Research project

  • Blood Proteins 100%
  • Coenzyme M 100%
  • Doxorubicin 100%
  • Plasma Protein 100%
  • Mesna 100%

• An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination with Rituximab Compared to a Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory, CD22- Positive, Follicular B-Cell

  Fleischman, R. (PI)

  Wyeth Pharmaceuticals Inc

  5/1/08 → 8/31/09

  Project: Research project

• A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid) in Combination with Dexamethasone in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  Fleischman, R. (PI)

  Celgene

  8/1/07 → 7/31/09

  Project: Research project

• PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

  Fleischman, R. (PI)

  Eli Lilly and Company

  4/1/07 → 3/31/10

  Project: Research project

• A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

  Fleischman, R. (PI)

  Eli Lilly and Company

  4/1/07 → 9/30/14

  Project: Research project

• Favid-09: Favid-0:Phase II Trig of Favid (Patient Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive Favid on Study Favid 06

  Fleischman, R. (PI)

  Favrille Inc

  4/1/05 → 6/30/08

  Project: Research project

• Favid-06: Phase III, Randomized, Double Blind Placebo-controlled Trial of Favid and GM-CSF versus Placebo and GM-CSF Following Rituximab in Subjects with Follicular B-Cell Non-Hodgkin's Lymphoma

  Fleischman, R. (PI)

  Favrille Inc

  7/9/04 → 10/31/09

  Project: Research project

• A Randomized, Open-Label Study of darbepoetin alfa (Novel Erythropoises Stimulating Protein, NESP) Using Fixed and Weight-Based Dosing for the Treatment of Anemia in Subjects with Non-myeloid Malignancies Receiving Multicycle Chemotherapy

  Fleischman, R. (PI)

  AMGen

  12/1/01 → 12/31/05

  Project: Research project

• A Phase IV, Open-Label, Multicenter, Randomized Study of NEUMEGAR (Recombinant Human Interleukin Eleven Growth Factor, rhIL-11) in Patients with Lymphoma and Chemotherapy

  Fleischman, R. (PI)

  Genetics Institute

  12/1/00 → 11/30/01

  Project: Research project

• Titan Pharmaceutical, Anti-Id Protocols

  Fleischman, R. (PI)

  Titan Pharmaceuticals

  11/1/00 → 10/31/03

  Project: Research project

• 00-MHL-15 Randomized, Double-Blind, Placebo-Controlled, Trial of Primary Prophylaxis with rh-TPO Administered to Patients Receiving DHAP Chemotherapy for Non-Hodkin's Lymphoma

  Fleischman, R. (PI)

  Pharmacia & Upjohn Inc

  9/1/00 → 10/31/02

  Project: Research project